Endocyte Cultura da Companhia

Dr. Christopher P. Leamon, Ph.D. has been a Vice President of Research & Development of Endocyte, Inc. since August 27, 2016. Dr. Leamon has 15 years experience in the drug delivery field. Dr. Leamon is credited for conducting the initial experiments in folate-targeted technology and for exemplifying this novel therapeutic approach for treating cancer. Prior to joining Endocyte in February 1999, Dr. Leamon was employed in the pharmaceutical industry, conducting discovery research in the field of peptide, oligonucleotide and DNA plasmid drug delivery for GlaxoWellcome, Inc. and Isis Pharmaceuticals, Inc. At Endocyte he remains active in radiopharmaceutical, chemotherapeutic and gene therapy research and development. Dr. Leamon received his Ph.D. in Biochemistry from Purdue University and holds B.S. in chemistry at Baldwin Wallace College.

Dr. Philip S. Low, Ph.D., is a Founder of Endocyte, Inc. and has been its Chief Science Officer since April 1998. Dr. Low serves as Joseph F. Foster Professor of Chemistry and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low has spent over 14 years in drug delivery research. He has been a Director of Endocyte, Inc. since December 1995. Dr. Low serves as Member of Scientific Advisory Board at IVDiagnostics, Inc. He has served National Institutes of Health Study Sections and has received both of Purdue's awards for outstanding research; namely the Sigma Xi award and Herbert Newby McCoy Award. He has published over 160 scientific articles. He holds BS in Chemistry from Brigham Young University. Dr. Low received his Ph.D. in Biochemistry from University of California, San Diego in 1975.

Dr. Alison A. Armour, M.B.,Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR has been Chief Medical Officer at Endocyte, Inc. since August 2015. Dr. Armour served as Vice President of Oncology at Novartis and GSK, where she led the global strategic TYKERB development team in breast cancer and was accountable for a large matrix team composed of clinical, medical, regulatory, statistics, medical affairs, science and commercial colleagues based in multiple sites in the US, UK and Japan. She was the Global Medical Science Director at AstraZeneca and led the development and approval of IRESSA. Dr. Armour established herself as a thought leader in medical and radiation oncology. Dr. Armour holds her B.Sc. in Biochemistry, M.B., Ch.B. MSc and Doctorate of Medicine from the University of Glasgow. MRCP at the Member of the Royal College of Physicians Glasgow and her FRCR at the Royal College of Radiologists London, UK.

Caryn Barnett serves as the Vice President Clinical Operations of Endocyte. Caryn started at Endocyte in Nov of 2018. Caryn currently resides in the Indianapolis, Indiana Area.

Chris Leamon serves as the Vice President, Research of Endocyte. Chris started at Endocyte in Feb of 1999. Chris currently resides in the Lafayette, Indiana Area.

Richard Messmann serves as the Vice President, Medical Affairs of Endocyte. Richard started at Endocyte in Jun of 2016. Richard currently resides in the Indianapolis, Indiana Area.